Cancer is responsible for one out of three deaths for men and one out of four for women. Since 1989, it has been the primary cause of death in France, ahead of cardiovascular diseases. Even if there has been undeniable progress made the past 15 years in terms of screening, diagnostics, and care (targeted therapies, personalised medicine), the medical needs and expectations of society remain very important.
However, to offer new chances to patients, it is essential to cooperate and develop competencies and talents. This is the shared vision of Roche and AREVA Med. In France, Roche founded in 2011 the first institute dedicated to partnership research, IRRMT. The Roche – AREVA Med program could lead to the development of highly-targeted cancer treatments based on radio-immunotherapy, a technology which is today part of a growing number of preclinical and clinical research programs in France as well as the United States.